Introduction {#Sec1}
============

Methicillin-resistant *Staphylococcus aureus* (MRSA) represents a major cause of infections in both the hospital and the community. The virulence of this pathogen partially relies on extracellular molecules. Panton-Valentine leukocidin (PVL, composed of *LukS-PV* and *LukF-PV*), a pore-forming toxin causing leukocytolysis and tissue necrosis, is one of these virulence factors that may have a significant influence in some serious *Staphylococcus aureus* (*S. aureus*) infections, such as severe skin and soft tissue infection, necrotizing pneumonia, and necrotizing fasciitis^[@CR1],[@CR2]^. To date, PVL-producing MRSA isolates have emerged throughout the world^[@CR2]--[@CR10]^, and pose a huge threat to the health of patients. In Britain and France, therapeutic regimens may be regulated based on the existence or the absence of *S. aureus* PVL toxin^[@CR11]^. The toxin-suppressing antibiotics, such as clindamycin, linezolid, and rifampin, are suggested for treating patients with serious PVL-expressing isolate infections^[@CR11]^.

Previous reports have illustrated sequence variations within the *lukSF-PV* genes^[@CR8],[@CR12]--[@CR15]^. Molecular modeling indicates that a single amino acid replacement at site 176 \[histidine (His) to arginine (Arg), namely H isoform changing into R isoform\] may increase the leukotoxicity of PVL^[@CR8]^. However, no evidence supports this assertion in the laboratory and clinical studies^[@CR13],[@CR16]^. Genestier *et al*.^[@CR17]^ reported that the role of PVL depends on the amount of toxin generated by *S*. *aureus*. Moreover, the only existence of a virulence gene does not imply that the toxin will be transcribed and/or translated and, if it is transcribed and/or translated, the toxin yield can be significantly different among isolates^[@CR6]^. Therefore, this study detected the *in vitro* PVL production in clinical *lukSF-PV* positive (*lukSF-PV*^+^) MRSA isolates and explored whether the quantitative generation of PVL is correlated with specific isoform. In addition, the study also further analyzed the correlation of PVL production with clonal complexes (CCs) of isolates and type of infection.

Results {#Sec2}
=======

Clinical features {#Sec3}
-----------------

Fifty-one *lukSF-PV*^+^ MRSA isolates were isolated from 31 adult patients (including 14 young and 17 middle-aged and elderly patients), 1 adolescent, and 19 pediatrics (containing 9 children aged \<1 year and 5 neonates aged \<28 days). Of the 51 isolates, 19 were related to skin and soft tissue infections (SSTI), 16 to pneumonia, 5 to surgical site infections, and 11 to other infections (1 bacteremia, 1 urinary tract infection, 1 acute bacterial tracheitis, 4 tympanitis, and 4 conjunctivitis). According to the case notes, 22 (43.1%) and 29 (56.9%) MRSA were established as hospital-associated (HA) isolate and community-associated (CA) isolate, respectively (Table [1](#Tab1){ref-type="table"}). Of 34 patients aged ≤44 years, 27 (79.4%) had CA infections. However, among 17 patients aged ≥45 years, only 2 (11.8%, 2/17) had CA infections (Table [1](#Tab1){ref-type="table"}, ages of patients not shown).Table 1Characteristics of 51 *lukSF-PV*^+^ MRSA isolatesInfection type, isolate (*n*)CA/HAMolecular characteristicIsoform of PVLSCC*mec* typePFGE typeMLST typeCCPneumonia (16)  PVL74CAH2IIIA1ST59CC59  PVL130HAH1IIIF2ST59CC59  PVL161CAH2NTKST188CC1  PVL211HAH1IIIE1ST22CC22  PVL212HAH2IVaG1ST59CC59  PVL214HAH2IIIE1ST22CC22  PVL217HAH2IIIG3ST59CC59  PVL219HAH2IIID2ST338CC59  PVL220HAH2IIID3ST338CC59  PVL222HAH2IIMST149CC5  PVL226HAH2IVaG2ST59CC59  PVL239HAH2IIIE2ST22CC22  PVL244HAH2NTWST88CC88  PVL254HAH2IIIB1ST59CC59  PVL255HAH2IIPST149CC5  PVL256CAH1IIIB1ST59CC59Skin and soft tissue infection (19)  PVL8CAH2IIIB3ST59CC59  PVL16CAH2IIIH1ST59CC59  PVL34CAH2IVaSST59CC59  PVL51CAH2IIIB3ST59CC59  PVL60CAH2IVaH2ST59CC59  PVL65CAH2IVaTST59CC59  PVL79CAH2IVaA3ST59CC59  PVL104CAR2NTXST88CC88  PVL108CAH2IIIF1ST59CC59  PVL145CAH2IIIF1ST59CC59  PVL148HAH2IVbOST9CC9  PVL150CAR2VJST25CC5  PVL170HAH2IIIA2ST59CC59  PVL195CAH2IIINST59CC59  PVL203CAH1IVaZST1CC1  PVL205HAH2IIIE1ST22CC22  PVL209HAH1IVaC1ST59CC59  PVL210CAH2IIIC3ST59CC59  PVL233CAH2IIIQST30CC30Surgical site infection (5)  PVL7CAH2VVST1CC1  PVL82HAH2IIIA1ST59CC59  PVL236HAH2IIIC4ST59CC59  PVL237CAH2IIIC2ST59CC59  PVL242CAH1IIID1ST338CC59Other infections (11)  PVL40CAR1IVaRST59CC59  PVL69HAH2IIILST217CC22  PVL186CAH2IVaA4ST59CC59  PVL202CAH2IVaYST88CC88  PVL204CAH2IIIC3ST59CC59  PVL206CAR2IVaUST25CC5  PVL218HAR2IVaI1ST59CC59  PVL221CAH2IIID1ST338CC59  PVL238CAH2IVaI2ST59CC59  PVL246CAH2IVaD4ST338CC59  PVL253HAH2IIIB2ST59CC59CA, Community-acquired isolate; HA, hospital-acquired isolate; MLST, multilocus sequence typing; NT, nontypeable; PFGE, pulsed-field gelelectrophoresis; SCCmec, staphyloccoccal cassette chromosome mec element; ST, sequence type.

*In vitro* production of PVL {#Sec4}
----------------------------

Twenty-nine (56.9%, 29/51) isolates generated PVL between 50 and 200 μg/mL, and 6 isolates had elevated PVL between 201 and 400 μg/mL; the remaining isolates (31.4%, 16/51) produced PVL less than 50 μg/mL. Pneumonia-related isolates yielded a mean \[±standard deviation (SD)\] of 72.11 ± 64.58 μg/mL and a median of 66.27 μg/mL PVL (Table [2](#Tab2){ref-type="table"}). This group contained one isolate (isolate PVL239) for which extremely low PVL generation (0.94 μg/mL) was measurable (Fig. [1A](#Fig1){ref-type="fig"}). SSTI-associated isolates produced an average of 126.58 ± 90.67 μg/mL and a median of 113.63 μg/mL PVL (Table [2](#Tab2){ref-type="table"}), among which one isolate (isolate PVL51) was the highest producer (360.87 μg/mL) (Fig. [1C](#Fig1){ref-type="fig"}). For the other infection-related isolates, an average PVL level of 98.34 ± 102.79 μg/mL and a median of 75.79 μg/mL were found (Table [2](#Tab2){ref-type="table"}). This group included one isolate (isolate PVL202), which was the lowest producer (0.43 μg/mL) (Fig. [1D](#Fig1){ref-type="fig"}). Surgical site infection--associated isolates generated the lowest PVL quantity (a mean of 59.55 ± 55.11 μg/mL and a median of 47.72 μg/mL) (Table [2](#Tab2){ref-type="table"} and Fig. [1B](#Fig1){ref-type="fig"}). Although the isolates from SSTI had relatively high values, the results from the Kruskal--Wallis test displayed no significant differences in PVL yields among the four different disease groups (*P* = 0.151).Table 2ELISA data on *in vitro* PVL production among clinical isolates of *lukSF-PV*^+^ MRSA (*n* = 51).GroupNumber of isolates (*n*)PVL range (μg/mL)PVL median (μg/mL)PVL mean ± SD (μg/mL)*P* valueClonal complex (CC)   Isolates belonging to CC59340.94**−**360.8780.75107.67 ± 91.92NA   Isolates belonging to CC2250.94**−**254.62118.51116.88 ± 75.98NA   Isolates belonging to CC8830.43**−**68.476.5325.14 ± 37.64NA   Isolates belonging to CC1313.65**−**145.3259.9172.96 ± 66.80NA   Isolates belonging to CC5414.67**−**88.3840.8546.18 ± 33.72NA   Isolates belonging to CC91NA   Isolates belonging to CC301NAType of infection   Isolates from SSTI1923.31**−**360.87113.63126.58 ± 90.670.151   Isolates from pneumonia160.94**−**254.6266.2772.11 ± 64.58   Isolates from surgical site infection53.48**−**128.2747.7259.55 ± 55.11   Isolates from other infection110.43**−**339.5275.7998.34 ± 102.79   CA isolates290.43**−**360.8768.47105.2 ± 96.60.754   HA isolates220.94**−**265.8087.5886.8 ± 68.8Isoform of PVL   H isoform isolates460.43**−**360.8780.7596.91 ± 86.410.975   R isoform isolates523.82**−**231.7468.4796.09 ± 80.40CA, Community-associated infection; HA, hospital-associated infection; NA, not applicable for the Kruska--Wallis rank-sum test due to a relatively small number of isolates; PVL, Panton--Valentine leukocidin; SD, standard deviation; SSTI, skin and soft tissue infection.Figure 1PVL yield of 51 clinical *lukSF-PV*^+^ MRSA isolates in a given infection classification. Isolates were grouped on the basis of the clinical diagnosis, and PVL generation was examined using ELISA. Error bars signify SDs of the results from three experiments for each isolate.

Among all CCs, the CC22 isolates produced the highest level of PLV (a mean of 116.88 ± 75.98 μg/mL and a median of 118.51 μg/mL), followed by CC59, CC1, CC5, and CC88 isolates (Table [2](#Tab2){ref-type="table"}). Although the PVL levels of isolates with CC88 and CC5 were far lower than those of CC22 and CC59 isolates, the statistical analysis was not performed to analyze the significance of the difference because of the small number of isolates of most CCs (Table [2](#Tab2){ref-type="table"}). In addition, this study also analyzed the correlation of PVL yields of isolates with CA and HA infections, and PVL H and R isoforms. Unfortunately, no statistical differences were found among them (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec5}
==========

Among *lukSF-PV*^+^ MRSA, 66.7% (34/51) were isolated from young and pediatric patients (≤44 years old), which included 93.1% (27/29) CA MRSA. This was consistent with the reports that CA MRSA mostly affects young individuals and children, and usually presents PVL^[@CR18]^.

Previous reports showed that the *lukSF-PV* genes were a frequent genetic marker of CA MRSA isolates with SCC*mec*IV or SCC*mec*V^[@CR19],[@CR20]^. Nevertheless, some studies have reported the *lukSF-PV*^+^ HA MRSA strains^[@CR21]--[@CR25]^. This study also found that 43.1% (22/51) *lukSF-PV*^+^ MRSA were HA MRSA strains (Table [1](#Tab1){ref-type="table"}). The prevalence of *lukSF-PV*^+^ MRSA clonal lineages is diverse in different parts of the earth. For example, ST8 (CC8)-SCC*mec*IV (USA300) clone predominates in USA; ST59 (CC59)-SCC*mec*V~T~ clone circulates in Asia, ST30 (CC30)-SCC*mec*IV clone is prevalent in New Zealand, ST93 (CC93)-SCC*mec*IV clones are found mainly in Australia, ST80 (CC80)-SCC*mec*IV is the most frequent clone in Europe and the Middle East, ST88 (CC88)-SCC*mec*IV clone is identified mainly in Africa, and ST22 (CC22)-SCC*mec*IV and ST772 (CC1)-SCC*mec*V clones emerge mainly in India^[@CR18]^. In the present study, ST59 (CC59)-SCC*mec*III was the predominant clone (35.3%, 18/51) of *lukSF-PV*^+^ MRSA isolates, followed by ST59 (CC59)-SCC*mec*IV (IVa/IVb, 25.5%, 13/51). However, for the former, 61.1% (11/18) of isolates were found to be CA MRSA; for the latter, 38.5% (5/13) of isolates were detected as HA MRSA. Historically, SCC*mec*III was considered as one of the epidemiological markers of the main HA MRSA clones, and SCC*mec*IV was often found in CA MRSA isolates^[@CR24]^. However, contrary to these views, SCC*mec*III and SCC*mec*IV were found in both HA and CA *lukSF-PV*^+^ MRSA isolates in this study. This indicated that the *lukSF-PV*^+^ MRSA isolates carrying SCC*mec*III or SCC*mec*IV could disseminate between the hospital and the community in the region studied. The PFGE types of some isolates with SCC*mec*III supported the possibility of the transmission of HA strains of SCC*mec*III into the community (Table [1](#Tab1){ref-type="table"}). In addition, the reports by Song *et al*.^[@CR26]^ and Yao *et al*.^[@CR24]^ also described this spread of HA and CA MRSA isolates from Taiwan, Hong Kong, Korea, Vietnam, and Wenzhou city of mainland China. Geng *et al*.^[@CR27]^ reported the existence of ST338 (CC59) CA MRSA isolate in Taiwan and the southern region of China. In the present study, five *lukSF-PV*^+^ MRSA isolates were also identified to be ST338 type, including three CA isolates and two HA isolates. The investigation results of Song *et al*.^[@CR26]^ showed that ST30 (CC30) was predominant in Asian areas. However, only one HA isolate was ST30 in this study. Additionally, ST22 (CC22) and ST88 (CC88), predominating in India^[@CR28],[@CR29]^ and Africa^[@CR3]^, respectively, were also found in the isolates in this study. However, the ST22 isolates were SCC*mec*III type, and not SCC*mec*IV detected in India. Although ST8 (CC8) and ST80 (CC80) prevailing in the USA and Europe, respectively, have been described in CA MRSA isolates from Japan and Korea (ST8), and Singapore and Malaysia (ST80), both MRSA clones are apparently scarce in Asian regions^[@CR26]^ and were not found in the isolates in this study (Table [1](#Tab1){ref-type="table"}).

According to the reports of Dumitrescu *et al*.^[@CR12]^, O'Hara *et al*.^[@CR8]^, and Tong *et al*.^[@CR14]^, the R isoform of PVL was found in CC8 (mainly USA300 strains), CC1, and CC93 isolates, which were mainly from the USA and Australia; while the H isoform was mainly observed in non-USA isolates belonging mainly to CC121, CC30, and CC22. A few isolates belonging to CC1, CC5, CC6, CC25, CC59, and CC88 also carried the H isoform. Table [1](#Tab1){ref-type="table"} shows that the H isoform was harbored by 90.2% (46/51) of *lukSF-PV*^+^ MRSA isolates belonging primarily to CC59 (69.6%, 32/46), followed by CC22 (10.9%, 5/46), CC88 (6.5%, 3/46), CC5 (6.5%, 3/46), CC1 (6.5%, 3/46), CC9 (2.2%, 1/46), and CC30 (2.2%, 1/46); however, the R isoform was found only in five isolates belonging to CC59, CC88, and CC5, which were different from those (CC8, CC1, and CC93) described by the previous studies^[@CR8],[@CR12],[@CR14]^.

PVL can lead to concentration-dependent necrosis and apoptosis of human polymorphonuclear neutrophils and lysis of human monocytes and macrophages^[@CR12]^, but whether PVL is pathogenic or a marker of specific infection is controversial. Contradictory data may be associated with the quantity of PVL generated by individual isolates. Up to now, the number of *S. aureus* isolates producing PVL is mainly determined using polymerase chain reaction (PCR) for *lukSF-PV* genes or quantitative reverse transcription--PCR for *lukSF-PV* mRNA levels. However, the findings of these methods may not relate to the actual yield of PVL. Therefore, the present study directly detected the PVL toxin production using enzyme-linked immunosorbent assay (ELISA). This study showed that all the *lukSF-PV*^+^ isolates produced PVL *in vitro*, and the extent of the toxin expression varied among isolates (range from 0.43 to 360.87 μg/mL), even within specific genetic contexts (Table [2](#Tab2){ref-type="table"}).

Undoubtedly, the presence of the genes encoding PVL does not necessarily imply that the toxin is produced in the setting of human infection. While this is true, it is important to note that neither does *in vitro* production. Additionally, the production of toxin is varied from culture media. Historical documents have reported the inter-isolate variability for ST8, ST80, ST93, and ST121 isolates^[@CR6],[@CR11],[@CR30]^. The same phenomenon was reported for the STs detected in this study. The data showed that two ST59 CA isolates (PVL51 and PVL238) were the strongest producers of PVL (360.87 μg/mL and 339.52 μg/mL, respectively); and three ST59 (PVL8, PVL40, and PVL209) and one ST22 (PVL211) isolates produced 231.74--265.80 μg/mL of PVL (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). However, two extremely low producers of PVL also belonged to ST59 and ST22 clones (PVL202 and PVL204, 0.94 μg/mL each) (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). The amounts of PVL yielded by other MRSA isolates (including the remaining ST59 and ST22 isolates) varied between 0.43 and 192.96 μg/mL. The cause of the difference in PVL expression is not clear. Also, the correlation of PVL yield with the genetic background of isolates warrants further investigation. The PVL concentration of 0.33 μg/mL evoked the apoptosis of human granulocytes, and the injection of 0.3 μg/mL of toxin into the intracutaneous tissue of rabbits caused local inflammation and necrosis^[@CR11]^. According to the *in vitro* PVL production in this study (≥0.43 μg/mL), all *lukSF-PV*^+^ isolates likely had the ability to cause an inflammatory response during infections. Shallcross *et al*.^[@CR31]^ reported that PVL-producing clinical isolates had a link with SSTIs. In the present study, the mean value and median of PVL production of SSTI isolates were relatively high compared with those of isolates from pneumonia, surgical site infections, and other infections. However, the significant difference in the toxin levels was not found among the four groups (Table [2](#Tab2){ref-type="table"}). This result was not consistent with the conclusion that PVL performed a more significant role in *S. aureus* SSTIs^[@CR31]^. In addition, the isolates from invasive infections (such as pneumonia) were even shown to yield low mean and median of PVL (Table [2](#Tab2){ref-type="table"}). The possible explanation was that the clinical outcome was correlated with host factors, or with the existence of other toxins^[@CR30]^.

For PVL variants, the H and R isoform isolates generated similar mean concentrations and medians of PVL, and the difference between the two groups was not significant (*P* = 0.975) (Table [2](#Tab2){ref-type="table"}). This result suggested that point mutations in the open reading frame of *lukSF-PV* genes might have no effect on the toxin production.

A previous study showed that CA MRSA infection was responsible for rapidly progressive and lethal diseases such as necrotizing pneumonia, severe sepsis, and necrotizing fasciitis. Also, some data sustained the opinion that PVL was accountable at least partially for the enhanced virulence of CA MRSA^[@CR32]^. In this study, the CA and HA isolates yielded similar levels of PVL (*P* = 0.754) (Table [2](#Tab2){ref-type="table"}). This indicated that the *lukSF-PV*^+^ HA isolates might lead to the severity of clinical infections similar to that caused by *lukSF-PV*^+^ CA isolates.

Being a retrospective study, this study had several limitations. First, the corresponding clinical samples could not be collected to evaluate the actual concentration of PVL *in vivo*. Because the PVL production depends on many factors, such as environmental factors, host factors, and internal factors of bacteria, it is not yet known which factor impacts mainly on the protein expression level. Second, the representativeness of isolates from only one hospital was insufficient for determining the generation and isoforms of PVL and the association between PVL production and PVL variants or genetic background or infection types. Third, more clinical information could not be collected to evaluate the correlation of the yield and isoform of PVL with the severity of illness.

In summary, the present experimental data did not sustain the direct correlation of PVL production *in vitro* with clinical types of infection and its isoform. The *in vitro* production of PVL by *lukSF-PV*^+^ MRSA isolates was dramatically changeable, indicating the existence of unknown environmental and host factors in transcriptional and/or translational regulation of gene expression. The regulation mechanisms affecting the differential expression of PVL and the associations among PVL levels and characteristics of isolate and infection require further exploration.

Methods {#Sec6}
=======

Clinical isolates {#Sec7}
-----------------

Fifty-one consecutive, nonduplicate *lukSF-PV*^+^ MRSA isolates from various clinical specimens of individual patients were obtained from Zhejiang Xiaoshan Hospital (a tertiary hospital), Hangzhou City, China. The isolates were collected between January 2010 and December 2011 and identified using VITEK 32 instrument (bioMérieux, Marcy l′ Etoile, France). Methicillin resistance was determined using the Kirby--Bauer method with cefoxitin disk (30 µg, Oxoid, Basingstoke, UK) and PCR for mecA^[@CR33],[@CR34]^. All isolates had been previously described by PVL isoform detection and PFGE-SCCmec-MLST typing (including CC) (Table [1](#Tab1){ref-type="table"})^[@CR35]^. The strains ATCC 49775 and MRSA N315 were used as positive and negative controls for the PVL production, respectively.

Quantitative detection of PVL {#Sec8}
-----------------------------

For quantifying the production of PVL *in vitro*, a certain amount of *lukSF-PV*^+^ MRSA (1 to 3 × 10^6^ CFU/mL) was cultured at 37 °C in 5 mL of casein--casein--yeast extract broth in which the optimal production of PVL could be acquired, with shaking at 200 rpm for 20 h. At this time, all growth isolates had reached a survival plateau of 1 to 4 × 10^9^ CFU/mL^[@CR6],[@CR11]^. Culture supernatants were acquired by centrifugation at 8000 *g* for 15 min. The quantification of secreted PVL was performed using ELISA, according to the kit instructions (Shanghai Y-J Biotechnology Co., Ltd., China). Each sample was measured in triplicate. The ELISA detection limit of PVL was 0.3\~10 μg/mL. The samples with a concentration of more than 10 μg/mL were diluted for the redetection of PVL. A previous study reported that the intracutaneous injection of 0.3 μg/mL PVL led to local inflammation and necrosis in rabbits, which, like humans, are sensitive to similar PVL concentration^[@CR11]^. Therefore, a concentration of 0.3 μg/mL was used in the present study, just the lower detection limit of the ELISA kit, as the cutoff value to determine whether the supernatant was PVL positive.

Definitions {#Sec9}
-----------

\(1\) SSTI was described as the existence of a skin abscess or other symptoms of inflammation and a positive MRSA culture^[@CR36]^. (2) Pneumonia was described as the existence of fever with imaging changes corresponding to pulmonary infection and MRSA-positive respiratory tract specimens (sputum, endotracheal aspirate, bronchial washing, and bronchoalveolar lavage) or blood cultures^[@CR36]^. (3) Surgical site infection was defined as an infected postoperative wound and drainage with a positive MRSA culture^[@CR36]^. (4) Primary bacteremia was defined as the existence of a blood culture positive for MRSA without the recognizable origin of infection^[@CR36]^. (5) Urinary tract infection was defined as MRSA bacteriuria (≥105 CFU/mL) and pyuria. (6) Acute bacterial tracheitis was diagnosed according to the presentation of upper respiratory tract obstruction, such as stridor, cough, and dysphagia; abundant purulent tracheal excretions; and positive culture for MRSA from the tracheal excretions. (7) Tympanitis was defined as the inflammation of the middle ear with a positive MRSA culture. (8) Conjunctivitis was characterized as a positive culture for MRSA plus two or more of the following symptoms: red, watery, itchy eyes; painful, burning eyes; purulent fluid in eyes; or photophobia. (9) CA MRSA infection was described as MRSA infection emerging in the community or within 48 h after admission to hospital without established risk factors (such as hospitalization history, surgery, dialysis, or living in a long-term care residence within 1 year; existence of a long-term indwelling catheter or other percutaneous medical device; or previous MRSA isolation). (10) HA MRSA infection was characterized as strains isolated from patients in less than 48 h of hospitalization with the aforementioned risk factors or \>48 h of admission^[@CR37]^.

Clinical information {#Sec10}
--------------------

The clinical data of the patients were collected retrospectively from the case notes. The data included gender, age, outpatient or inpatient, clinical symptoms, sample type, date of strain isolation, clinical diagnosis, and other medical histories related to HA or CA infections.

Statistical analysis {#Sec11}
--------------------

In view of the uneven distribution of PVL production among isolates, the comparisons of two and ≥3 groups were analyzed using the Wilcoxon rank-sum test and the Kruskal--Wallis rank-sum test (SPSS 22.0), respectively. A two-sided *P* value \< 0.05 was considered statistically significant.

Data availability {#Sec12}
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